Pharmaceutical Manufacturing & Drug Delivery Technologies
Strategic Profile
Gelteq is a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Recent announcements include a multi-year sales agreement with a healthcare and wellness distributor in China for a sugar-lowering nutritional gel, collaborations with nutraceutical partners launching products in the U.S., and sports performance partnerships with national flag football programs and professional leagues in Asia and Australia. The company is expanding manufacturing capacity through partnerships with established pharmaceutical contractors.
Cyborg Score Rationale
Gelteq announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product, demonstrating a 38–45% increase in systemic exposure and absorption (AUC). The company has established strategic partnerships for manufacturing and distribution globally, positioning it for potential scale-up. Micro-cap status presents execution and market risk.
Top Insights
Gelteq's formulation demonstrated a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax), while maintaining a comparable time to peak plasma concentration (Tmax).
Gelteq entered a three-year sales agreement with Shenzhen Mana Health Management to distribute its proprietary gel nutritional formulation across China, with Gelteq expecting to derive a minimum of approximately USD $1.3 million in revenue during the three-year term.
Gelteq entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.
Gelteq entered into a Product Development and Profit Share Agreement with Melbourne Health, operator of The Royal Melbourne Hospital, to develop new products incorporating high-amylose maize starch butyrylated (HAMSB), a unique compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer.
Named Competitors
Modified Release Technology — Pharmaceutical coating and delivery systems
Taste Masking Solutions — Specialty chemical delivery platforms
Soft Gel Capsules — Contract pharmaceutical manufacturing and delivery
Recent Developments
(November 2025) Announced positive preclinical pharmacokinetic results showing 38-45% increase in systemic exposure versus leading marketed antihistamine
(October 2025) Entered Product Development and Profit Share Agreement with Melbourne Health for HAMSB-based bowel polyp reduction products
(July 2025) Signed memorandum of understanding with IDT Australia for dedicated gel-based product manufacturing facility
(2025) Multi-year sales agreement with Shenzhen Mana Health Management for sugar-lowering nutritional gel distribution in China
Open the full interactive Gelteq Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.